Clinical outcome of primary non-metastatic breast cancer: A single institution experience

Jamshed, Arif; Shah, M. A.; Syed, Akbar; Murtaza, Ghulam; Mehmood, Tahir; Chaudry, Samreen Javed; Loya, Asif; Hameed, Shahid

doi:10.4103/0019-509x.175599

Cited by 6 publications

(11 citation statements)

References 1 publication

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Factors affecting DFS and OS: age, lymph node involvement, lymphovascular invasion, tumour stage, adjuvant anthracycline-based chemotherapy and type of surgery (not significant for DFS). Three-year DFS and OS:72.0 and 93.0%, respectively Jamshed et al 2015, India (Asia) [ 13 ] Clinical outcome of primary NMBC: A single institution experience Fifteen-year single-center retrospective study:2829 cases The median follow-up: 4.4 years. Recurrence following primary treatment was seen in 35% of the patients: 5% local, 1% regional, and 29% distant.…”

Section: Resultsmentioning

confidence: 99%

Evolutionary aspects of non-metastatic breast cancer after primary treatment in a sub-Saharan African setting: a 16-year retrospective review at the Douala general hospital, Cameroon

et al. 2018

View full text Add to dashboard Cite

BackgroundBreast cancer has a high case fatality rate in sub-Saharan Africa, and this is chiefly because of late detection and inadequate treatment resources. Progressive renovations in diagnostic and management modalities of non-metastatic breast cancer (NMBC) have been noted in the region but there is paucity of data describing the clinical progress of patients with NMBC. This study sought to determine the rates of local relapse, distant metastasis and sequelae and the time span from initial treatment to the occurrence of these adverse events among patients with NMBC.MethodsThis was a retrospective review of medical records of patients with histologically confirmed NMBC at the department of radiation therapy and oncology of the Douala General Hospital in Cameroon from the January 1997 to December 2012 period. Clinicopathological and treatment characteristics as well as occurrences of adverse events were studied.ResultsA total of 260 cases were reviewed of which 224/260 (86.2%) had invasive ductal carcinoma. Surgery was performed on 258/260 cases (99.2%) with 187/258 (72.5%) being modified radical mastectomies. Various treatment combinations were used in up to 228/260 patients (87.5%) while surgery alone was the treatment in the remaining 32 cases (12.5%). Metastasis occurred in 142/260 cases (54.6%) of which 68/142 (26.2%) were local relapses and 74/142 (28.5%) were distant metastases. Among the cases of distant metastasis, 9.2% were bone, 8.5% lungs, 6.9% nodal, and 5.4% brain. Metastasis to multiple organs was noted in 4.7% of these cases. The median periods of occurrence of local relapse and distant metastases were 13 and 12 months respectively. Sequelae occurred in 26/260 cases (10%) and were noted after an average of 30 months. The main sequelae were lymphoedema (6.5%) and lung fibrosis (1.5%). At the end of the period under review, 118/260 patients (45.4%) were alive and disease-free with a median follow up time of 24 months.ConclusionsAdverse events were frequent among patients who received primary treatment for NMBC. Available cancer therapeutic modalities ought to be supplemented with efficient strategies of follow-up and monitoring so as to optimize the care provided to these patients and improve on their survival.

show abstract

Section: Resultsmentioning

confidence: 99%

Evolutionary aspects of non-metastatic breast cancer after primary treatment in a sub-Saharan African setting: a 16-year retrospective review at the Douala general hospital, Cameroon

et al. 2018

View full text Add to dashboard Cite

show abstract

“…For example, CK2 inhibitors decrease cell migration and invasion in human adenocarcinoma and NSCLC cell lines, seemingly through downregulation of MMP-2 transcript expression and activity via the ERK pathway [ 54 ]. In SCLC and LCLC (large cell lung cancer), cell proliferation, but not cell invasion, is highly sensitive to Quinalizarin [ 55 ]. In contrast, in one adenocarcinoma cell line, invasion and apoptosis, but not proliferation, were sensitive to Quinalizarin [ 55 ].…”

Section: Discussionmentioning

confidence: 99%

“…In SCLC and LCLC (large cell lung cancer), cell proliferation, but not cell invasion, is highly sensitive to Quinalizarin [ 55 ]. In contrast, in one adenocarcinoma cell line, invasion and apoptosis, but not proliferation, were sensitive to Quinalizarin [ 55 ]. In other adenocarcinoma cell lines, Quinalizarin only leads to increased apoptosis [ 55 ].…”

Section: Discussionmentioning

confidence: 99%

CK2 in Cancer: Cellular and Biochemical Mechanisms and Potential Therapeutic Target

et al. 2017

View full text Add to dashboard Cite

CK2 genes are overexpressed in many human cancers, and most often overexpression is associated with worse prognosis. Site-specific expression in mice leads to cancer development (e.g., breast, lymphoma) indicating the oncogenic nature of CK2. CK2 is involved in many key aspects of cancer including inhibition of apoptosis, modulation of signaling pathways, DNA damage response, and cell cycle regulation. A number of CK2 inhibitors are now available and have been shown to have activity against various cancers in vitro and in pre-clinical models. Some of these inhibitors are now undergoing exploration in clinical trials as well. In this review, we will examine some of the major cancers in which CK2 inhibition has promise based on in vitro and pre-clinical studies, the proposed cellular and signaling mechanisms of anti-cancer activity by CK2 inhibitors, and the current or recent clinical trials using CK2 inhibitors.

show abstract

“…In a previous study, prognosis in the first 3 years of ER(+) tumors was shown to be good, although survival in the longer term was fairly poor. Gradually, endocrine therapy resistance is the main factor that blocks the success of hormonal treatment [14]. Chemotherapy in HR-negative patients is known to improve DFS and OS [7].…”

Section: Clinical Features and Differences Of Tumor Subgroupsmentioning

confidence: 99%

“…Additionally, 25-50% of ER+PR+ tumors are resistant to hormonal treatment. Genetic and non-genetic interferences between the ER and growth factors may lead to hormone resistance [14], but the exact mechanism that is implicated has not yet been understood. Genetic testing is not commonly performed to determine tumor subtypes or select treatment, and treatment alternatives are usually applied based on the receptor and clinicopathological data.…”

Section: Prognosis Survival and Risk Factors That Affect Themmentioning

confidence: 99%

Histopathological Characteristics: Clinical Course of Breast Cancer Subtypes Depending on the ER(+) (−)/PR(+) (−) Receptor Status

Bulut¹

2017

Breast Cancer - From Biology to Medicine

View full text Add to dashboard Cite

Breast cancer patients were divided into separate groups, which were the estrogen receptor ER +/progesterone receptor PR + HER −, the ER or PR+ HER −, the ER+/ PR+ HER +, the ER or PR+ HER +, the ER−/PR− HER −, and the ER−/PR− HER + groups. Patients with the ER/PR + /HER − subtype breast cancers show beter clinical prognosis compared to the hormone-negative, triple-negative TN , and HER + subtypes. TN, HER + tumors in postmenopausal women were of higher grade, showing lymph node and lymphovascular invasion with poor prognosis in all case series. However, the ER+/PR−/HER + subgroup had the lowest survival rates inand -year follow-ups. Comparison between the ER+PR+HER + and ER+PR−HER − subgroups showed that HER − status is an indicator of improved prognosis in longterm follow-up. Single hormone receptor HR + status, particularly HER − cases, was in between the favorable and poor survival subgroups. The ER−, PR−, and HER + properties were found to be risk factors for frequent recurrences. In this chapter, breast cancer subtypes are compared with each other. Results from diferent studies highlight the importance of ER/PR/HER receptor variations in the choice of treatment and prognosis of breast cancer.

show abstract

Clinical outcome of primary non-metastatic breast cancer: A single institution experience

Cited by 6 publications

References 1 publication

Evolutionary aspects of non-metastatic breast cancer after primary treatment in a sub-Saharan African setting: a 16-year retrospective review at the Douala general hospital, Cameroon

Evolutionary aspects of non-metastatic breast cancer after primary treatment in a sub-Saharan African setting: a 16-year retrospective review at the Douala general hospital, Cameroon

CK2 in Cancer: Cellular and Biochemical Mechanisms and Potential Therapeutic Target

Histopathological Characteristics: Clinical Course of Breast Cancer Subtypes Depending on the ER(+) (−)/PR(+) (−) Receptor Status

Contact Info

Product

Resources

About